Navigation Links
Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute
Date:5/15/2008

BONITA SPRINGS, Fla., May 15 /PRNewswire/ -- Tigris Pharmaceuticals, Inc. announced today the execution of a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to collaborate on clinical and preclinical development of AFP-464, an aminoflavone currently in Phase I development. AFP-464 is converted to metabolites which bind covalently to DNA, resulting in p53 activation and apoptosis.

This is part of a four-year CRADA encompassing multiple Phase I and Phase II clinical studies with correlating translational research of AFP-464 in a variety of tumor types. The goal of this research collaboration is to work together for the successful development of AFP-464 as a safe and effective novel pharmaceutical compound for the treatment of cancer. Under this CRADA, two Phase I studies with AFP-464 are currently enrolling in the United States, sponsored by the NCI, at the Mayo Clinic, Wayne State University, and the University of Maryland. These studies are evaluating AFP-464 in patients with advanced solid tumors. Tigris has also initiated a Phase I program at leading cancer research centers in Belgium and France; this work is not included in the CRADA research. The AFP-464 program is anticipated to move to Phase II development in 2009.

"It will be a privilege to work with the NCI on such a promising therapeutic for patients with cancer," stated Edmundo Muniz, M.D., Ph.D., Chief Executive Officer of Tigris. "This CRADA further solidifies the successful partnership to date between Tigris and the NCI."

About AFP-464

Preclinical studies into AFP-464's mechanism of action have shown that AFP-464 induces CYP1A1/1A2 and CYP1B1 protein expression and is converted to metabolites that are covalently bound to DNA, resulting in phosphorylation of p53 with induction of the p53 downstream target p21(Waf1/Cip1) and apoptosis. AFP-464 has shown a unique pattern of growth inhibitory activity in the NCI's 60 tumor ce
'/>"/>

SOURCE Tigris Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Tigris Pharmaceuticals Initiates Phase I Study of AFP-464 in Patients with Solid Tumors
2. VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial
3. Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute
4. Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury
5. Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Cytarabine
6. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
7. Poniard Pharmaceuticals Completes Enrollment of Phase 2 Picoplatin Trial in Colorectal Cancer
8. Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update
9. Alseres Pharmaceuticals Enters Agreement to Amend Cethrin(R) License to Lower Milestone Payments and Royalty Rates
10. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
11. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)...ISON, N.J., Dec. 3 A gen...of developing a potentially life-threatening blood...rapies or chemicals is one of several medical disc...est Diagnostics (NYSE: DGX ) will present during...ual Meeting and Exposition, December 5-8, 2009, in...
(Date:12/3/2009)...ILMINGTON, Del., Dec. 3 ParagonRx,...utical risk management and optimal medication use,... the FDA,s draft guidance on REMS - Risk Evaluatio...ons for REMS lifecycle management. Dr. Gary Slatk...t on REMS and risk management programs, will lead ...
(Date:12/3/2009)...N DIEGO, Dec. 3 Cardium ...at its wholly-owned subsidiary, Tissue Repair Comp...ing with the U.S. Food and Drug Administration (FD...TM) product candidate based on positive data from...clinical study. Today,s submission with the FDA c...
Breaking Medicine Technology:Quest Diagnostics Reveals New Genetic Discoveries for Testing for Leukemia, Lymphoma and Blood Clotting at 51st ASH Meeting and Exposition 2Quest Diagnostics Reveals New Genetic Discoveries for Testing for Leukemia, Lymphoma and Blood Clotting at 51st ASH Meeting and Exposition 3Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds 2Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds 3Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds 4Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds 5First 5 California Approves 2481 4 Million Contribution to Help Restore Healthy Families Programs Viability 54507 1First 5 California Approves 2481 4 Million Contribution to Help Restore Healthy Families Programs Viability 54507 2Some Birth Control Pills Safer Than Others 54505 1Some Birth Control Pills Safer Than Others 54505 2Some Birth Control Pills Safer Than Others 54505 3Chiropractors Focus on Patients Best Interest 54503 1
...ersome" vaginal atrophy, symptoms among sexually...women; results presented today at 19th Annual Nort...ciety Meeting, ANN ARBOR, Mich., Sept. 24 Additi...pemifene tablets) for the treatment of,symptoms of...n showed that,Ophena(TM) significantly improves a ...
...to Raise Awareness about,the Importance of Clinica...News facts:, -- Most Americans with cancer woul...rials if they knew about them. -- In a surve... unaware or unsure that participation in ...ive percent said they would have been willing to e...
Other Medicine Technology:QuatRx Pharmaceuticals Announces Additional Data From Phase 3 Study for Ophena(TM) (Ospemifene Tablets) Showing Improvements in Clinical Symptoms of Vulvovaginal Atrophy 2QuatRx Pharmaceuticals Announces Additional Data From Phase 3 Study for Ophena(TM) (Ospemifene Tablets) Showing Improvements in Clinical Symptoms of Vulvovaginal Atrophy 3QuatRx Pharmaceuticals Announces Additional Data From Phase 3 Study for Ophena(TM) (Ospemifene Tablets) Showing Improvements in Clinical Symptoms of Vulvovaginal Atrophy 4Video: The Looming Crisis in Cancer Drug Development: 97% of Adult Cancer Patients Do Not Take Advantage of Clinical Trial Programs 2Video: The Looming Crisis in Cancer Drug Development: 97% of Adult Cancer Patients Do Not Take Advantage of Clinical Trial Programs 3
(Date:12/4/2009)...Newswire/ -- The following is an op-ed by Jeffrey ...ies: ,, Credit Senators John Kerry (D-MA) and R... to the health care debate: a bill ends a glaring ...etonuria (PKU) control their potentially devastati... chronic conditions are treated. "The Medical Foo...
(Date:12/4/2009)...nal of Neurosurgery: Pediatrics finds that operat...oma, or JPA, tumors in the thalamus of the brain c...DTI. The sensitivity of DTI imaging allows for th...n. This information can maximize the potential of...ge to the fiber bundles that are directly related ...
(Date:12/4/2009)...rsonality, study finds , , FRIDAY, Dec. ...ne social network, such as Facebook, reveal the re...new study, which finds that people tend to express.... , "I was surprised by the findings because t... their profiles to promote an enhanced impression ...
(Date:12/4/2009)...ing manufacturer of over-the-counter topical cream...ers’ quality of life, today announced that i...Medical Association (APMA) Seal of Approval for it..., (PRWEB) December 4, 2009...he-counter topical cream and first aid products de...
(Date:12/4/2009)...company GemaTech launches its new approach to emer...t (PRU) is a call re-routing solution offered on a...ganisations to rapidly re-route their incoming cal...tion, with additional voice recording if desired, ...ion . , (PRWEB) December ...
Breaking Medicine News(10 mins):Health News:Health Leadership from Sen. Kerry and Sen. Casey: A Cure for Devastating Discrimination in Insurance Coverage for PKU Patients is on the Move 2Health News:Health Leadership from Sen. Kerry and Sen. Casey: A Cure for Devastating Discrimination in Insurance Coverage for PKU Patients is on the Move 3Health News:Online Identities Likely to Match Reality 2Health News:Tender Corp.'s HealthiFeet Awarded American Podiatric Medical Association Seal of Approval 2Health News:Tender Corp.'s HealthiFeet Awarded American Podiatric Medical Association Seal of Approval 3Health News:Tender Corp.'s HealthiFeet Awarded American Podiatric Medical Association Seal of Approval 4Health News:GemaTech Launches Portable Recovery Unit. The Latest Design in Emergency Telecoms Resilience and Continuity 2
...tarting Down syndrome infants on treadmill trainin...four or five months earlier than with only traditi...sity of Michigan says. , The study also suggests ... from locomotion: social skills, motor skills, adv...
...dyslexia struggle to read because their brains are..., according to a brain-imaging study published thi...euroscience (online October 16). The study found t...ding to the study,s first author, Nadine Gaab, PhD...
...alifornia will simultaneously open their doors We...ited to cover the,festivities, SAN FRANCISCO, Oct... a nursing home. Nurse administrators don,t often,...than 150 nursing homes in California this Hallowee...
...alifornia will simultaneously open their doors We...vited to cover the festivities, LOS ANGELES, Oct....a nursing home. Nurse administrators don,t often,s...han 150 nursing homes in California this Halloween...
...rn, a leading global clinical,research organizatio...al,Trial Management Services, Inc. (CTMS) a Bristo...ces throughout the United States. From February,20...ve experience conducting clinical trials in a wide...
...piest surprise this Halloween may actually be in t...turday at the American Heart Association conferenc...y mini-size Halloween candies when they kept the w...at the American Heart Association conference in Or...
Other Medicine News:Health News:Treadmill training helps Down syndrome babies walk months earlier 2Health News:Sound training rewires dyslexic children's brains for reading 2Health News:Sound training rewires dyslexic children's brains for reading 3Health News:Halloween Events in the Bay Area Bring Young and Old Together for a Ghoulish Good Time 2Health News:Halloween Events in Los Angeles Bring Young and Old Together for a Ghoulish Good Time 2Health News:Halloween Events in Los Angeles Bring Young and Old Together for a Ghoulish Good Time 3Health News:Chiltern Announces Acquisition of an Independent USA Based Clinical Research Organization, Clinical Trial Management Services, Inc. 2Health News:Food 'tricks' that combat sneaky, creepy Halloween treats 2
...VA for CELL-DYN are assayed linearity control kits... patient reportable range of three- and five-part ...linear performance of the analyzer. CVA and CVA fo... for each instrument model and provide instrument-...
LATITUDE® Patient Management System
...tary EX.P.R.T. Release Technology essentially elim... stent shortening,, Unique anatomically des...bifurcation,, 0.014 Rapid Exchange catheter...matic tip,, Radiopaque marker on catheter c...
...s a whole blood hematology control manufactured sp...d the Coulter AcT5diff instruments. The compositio...rential, positioning the populations within the li...oduct offers 105-day closed-vial stability and 14-...
Medicine Products: